Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 83, Issue 1, Pages 91-93Publisher
KLUWER ACADEMIC PUBL
DOI: 10.1023/B:BREA.0000010697.49896.03
Keywords
breast cancer; CHEK2; contralateral; mutation; radiation
Categories
Ask authors/readers for more resources
We detected a significant excess risk for CHEK2* 1100delC mutation carriers to develop a contralateral breast tumor, OR = 6.5 (95% CI 1.5 - 28.8, p = 0.005). The highest percentage of mutation carriers was detected among those bilateral breast cancer patients who had received radiation treatment for their first breast tumor. These results warrant prolonged medical surveillance and may indicate a clinically important interaction between CHEK2 heterozygosity and radiation in the development of contralateral breast cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available